tiprankstipranks
Trending News
More News >
Recursion Pharmaceuticals (RXRX)
NASDAQ:RXRX
US Market

Recursion Pharmaceuticals (RXRX) Income Statement

Compare
4,229 Followers

Recursion Pharmaceuticals Income Statement

Last quarter (Q3 2025), Recursion Pharmaceuticals's total revenue was $5.17M, a decrease of -80.16% from the same quarter last year. In Q3, Recursion Pharmaceuticals's net income was $-162.25M. See Recursion Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 58.84M$ 43.88M$ 39.68M$ 10.00M$ 3.41M
Gross Profit
$ 13.60M$ 1.29M$ -8.59M$ 10.00M$ 3.41M
Operating Expenses
$ 492.61M$ 351.35M$ 237.13M$ 192.78M$ 88.03M
Depreciation and Amortization
$ 36.49M$ 24.40M$ 11.76M$ 8.40M$ 3.94M
EBITDA
$ -426.72M$ -307.63M$ -227.66M$ -175.12M$ -81.70M
Operating Income
$ -479.00M$ -350.06M$ -245.73M$ -182.78M$ -84.61M
Other Income/Expenses
$ 14.22M$ 17.93M$ 6.25M$ -3.70M$ -2.39M
Pretax Income
$ -464.79M$ -332.13M$ -239.48M$ -186.48M$ -87.01M
Net Income
$ -463.66M$ -328.07M$ -239.48M$ -186.48M$ -87.01M
Per Share Metrics
Basic EPS
$ -1.69$ -1.58$ -1.36$ -1.05$ -0.52
Diluted EPS
$ -1.69$ -1.58$ -1.36$ -1.05$ -0.52
Weighted Average Shares Outstanding
274.21M 207.85M 175.54M 170.27M 165.79M
Weighted Average Shares Outstanding (Diluted)
274.21M 207.85M 175.54M 170.27M 165.79M
Currency in USD

Recursion Pharmaceuticals Earnings and Revenue History